H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences to $13 from $27 and keeps a Buy rating on the shares. The initial SUMMIT results shows that bezuclastinib is active, but it may not differentiate from the competition at this stage, the analyst tells investors in a research note. As such, the firm says bezuclastinib is now in a “show me” position.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on COGT:
- Wedbush downgrades Cogent Biosciences to Neutral, cuts price target to $5
- Cogent Biosciences just downgraded at Wedbush, here’s why
- Needham biotechnology analyst to hold an analyst/industry conference call
- Cogent Biosciences trading resumes
- Cogent Biosciences trading halted, volatility trading pause